Related Experiment Video
Updated: May 31, 2025
09:25
An In Vivo Duo-color Method for Imaging Vascular Dynamics Following Contusive Spinal Cord Injury
Published on: December 31, 2017
9.4K
The Critical Management of Spinal Cord Injury: A Narrative Review
Emilio Moreno-González1, Antonio Ibarra1
1Centro de Investigación de Ciencias de la Salud (CICSA), Facultad de Ciencias de la Salud, Universidad Anáhuac México Campus Norte, Huixquilucan CP 52786, Estado de México, Mexico.
Clinics and Practice
|January 24, 2025
Summary
Early intensive care unit (ICU) monitoring and standardized treatments improve spinal cord injury (SCI) prognosis. New neuroprotective agents show promise for better neurological outcomes in acute SCI patients.
Area of Science:
- Neurology
- Traumatology
- Critical Care Medicine
Background:
- Spinal cord injury (SCI) results from physical damage altering spinal cord function and structure.
- Traumatic causes like accidents and violence account for 90% of SCI cases.
- Early intensive care unit (ICU) monitoring is crucial for improving patient prognosis.
Purpose of the Study:
- To review current evidence on the acute management of spinal cord injury (SCI).
- To highlight the importance of prompt ICU admission and early decompression surgery.
- To explore the role of pharmacological agents in neuroprotection and improving outcomes.
Main Methods:
- Systematic review of 50 publications.
- Selection based on specific criteria for acute SCI management evidence.
- Analysis of current treatment strategies and emerging therapies.
Main Results:
- Standardized treatments for ventilatory, cardiopulmonary, and hematologic complications are key.
- These complications significantly impact long-term neurological and functional prognosis.
- Pharmacological agents are being investigated for neuroprotective properties.
Conclusions:
- Current acute SCI management requires standardized care focusing on physiological stability.
- Early intervention, including ICU monitoring and surgical decompression, is vital.
- Emerging neuroprotective agents in clinical trials offer potential for improved patient outcomes and warrant further investigation.
